Regulation of Siglec-8-induced intracellular reactive oxygen species production and eosinophil cell death by Src family kinases.
Siglec-8 is a surface receptor predominantly expressed on human eosinophils where its ligation induces reactive oxygen species (ROS) formation and cell death. Since Siglec-8 has intracellular tyrosine-based motifs, we hypothesized that Src family kinases (SFKs) are involved in ROS formation and cell death induced by Siglec-8 engagement.



Human peripheral blood eosinophils were purified and incubated with anti-Siglec-8 monoclonal antibodies (mAb, agonist), IL-5, and SFK pharmacological inhibitors. We focused on Siglec-8-induced cell death in short-term IL-5-activated cells leading to a regulated necrosis-type cell death. ROS production was determined by dihydrorhodamine (DHR) 123 labeling and flow cytometry, or by chemiluminescence using Amplex red. Activation of SFK was determined using phospholuminex and Western blotting.



In order to determine cellular localization of ROS production, we measured intra and extracellular ROS. While an ETosis stimulus (calcium ionophore A23187) led to extracellular ROS (ecROS) production, Siglec-8-engagement in short-term IL-5 activated cells led to intracellular ROS (icROS) accumulation. Consistently, inhibition of extracellular ROS by catalase inhibited ETosis, but not IL-5-primed Siglec-8-induced cell death. In order to determine signaling events for Siglec-8, we performed Western blotting and found SFK phosphorylation in lysates from eosinophils stimulated with anti-Siglec-8 mAb±IL-5. In order to identify which SFKs were involved, we used the phospholuminex assay and found increased levels of phosphorylated Fgr in the cytoplasmic fraction of cells co-stimulated with anti-Siglec-8 and IL-5 for 3 hours compared with cells stimulated with IL-5 alone. To test the involvement of SFKs in ROS production and cell death, we used SFK inhibitors PP2 and dasatinib, both of which completely inhibited eosinophil ROS production and cell death induced by anti-Siglec-8 and IL-5 co-stimulation.



Siglec-8 engagement in short-term IL-5-activated eosinophils causes icROS production and SKF phosphorylation, and both are essential in mediating Siglec-8-induced cell death.
Division of Allergy and Immunology, Cincinnati Children's Hospital Medical Center, United States; Department of Pediatrics, Kyoto Prefecture University of Medicine, Japan.
Gen
G
Kano
Division of Allergy-Immunology, Northwestern University Feinberg School of Medicine, United States.
Bruce S
BS
Bochner
Division of Allergy and Immunology, Cincinnati Children's Hospital Medical Center, United States; Department of Pathology and Laboratory Medicine, University of Cincinnati, United States. Electronic address: nives.zimmermann@cchmc.org.
Nives
N
Zimmermann
D015703:Antigens, CD / Q000378:metabolism*; D000944:Antigens, Differentiation, B-Lymphocyte / Q000378:metabolism*; D016923:Cell Death; D002478:Cells, Cultured; D004804:Eosinophils / Q000187:drug effects / Q000276:immunology / Q000378:metabolism*; D006801:Humans; D015848:Interleukin-5 / Q000378:metabolism / Q000494:pharmacology; D037102:Lectins / Q000378:metabolism*; D010766:Phosphorylation; D047428:Protein Kinase Inhibitors / Q000494:pharmacology; D017382:Reactive Oxygen Species / Q000378:metabolism*; D015398:Signal Transduction / Q000187:drug effects; D019061:src-Family Kinases / Q000037:antagonists & inhibitors / Q000378:metabolism*
D015703:Antigens, CD; D000944:Antigens, Differentiation, B-Lymphocyte; D015848:Interleukin-5; D037102:Lectins; D047428:Protein Kinase Inhibitors; D017382:Reactive Oxygen Species; C403967:SIGLEC8 protein, human; D019061:src-Family Kinases
Cell death; Eosinophils
Biochem Biophys Res Commun. 2005 Oct 28;336(3):918-24
16157303
Blood. 2013 Mar 14;121(11):2074-83
23303825
Pharmacol Ther. 2012 Sep;135(3):327-36
22749793
Blood. 2003 Jun 15;101(12):5014-20
12609831
Nat Rev Immunol. 2014 Oct;14(10):653-66
25234143
J Allergy Clin Immunol. 2015 May;135(5):1329-40.e1-9
25497369
J Immunol. 2009 Oct 15;183(8):5023-31
19794066
Biochemistry. 2013 Apr 16;52(15):2597-608
23418871
Cell Death Differ. 2011 Apr;18(4):656-65
21052097
Cell Metab. 2014 Jun 3;19(6):1020-33
24856931
Oncogene. 1998 Sep 24;17(12):1587-95
9794236
Front Immunol. 2012 Jan 11;2:96
22566885
J Allergy Clin Immunol. 2000 Jun;105(6 Pt 1):1093-100
10856141
J Immunol Methods. 2004 Aug;291(1-2):101-8
15345309
Blood. 2000 Jul 15;96(2):483-90
10887109
J Allergy Clin Immunol. 2013 Aug;132(2):437-45
23684072
Respir Res. 2010 Nov 01;11:154
21040544
Eur J Hum Genet. 2010 Jun;18(6):713-9
20087405
J Allergy Clin Immunol. 2015 Mar;135(3):598-608
25592986
J Pharmacol Exp Ther. 2009 Aug;330(2):608-12
19458105
J Immunol. 2013 Apr 1;190(7):3648-60
23447687
Immunol Rev. 2009 Mar;228(1):23-40
19290919
J Biol Chem. 2001 Nov 23;276(47):44315-22
11551923
Free Radic Biol Med. 2010 Dec 15;49(12):1834-45
20870019
Annu Rev Immunol. 2002;20:669-707
11861615
Blood. 2007 May 15;109(10):4280-7
17272508
J Allergy Clin Immunol. 2014 Jan;133(1):240-7.e1-3
23830412
J Biol Chem. 2000 Jan 14;275(2):861-6
10625619
Biochem J. 2009 Jan 1;417(1):1-13
19061483
Am J Respir Cell Mol Biol. 2008 Jan;38(1):121-4
17690326
J Allergy Clin Immunol. 2008 Feb;121(2):499-505.e1
18036650
Physiol Rev. 1994 Jan;74(1):139-62
8295932